Drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program. Eligible patients will be able to buy the drug directly through the Eliquis 360 Support program from September 8 at a rate that is more than 40% lower than the current list price.
"Eliquis is the nation's number one prescribed oral anticoagulant that provides important benefits to patients and the healthcare system," said Bristol Myers CEO Christopher Boerner.
"This program passes more savings directly to patients."
Since its launch, Eliquis has been prescribed to over 15 million Americans and in 2024 it generated about $11.4 billion in global revenue.
